Abstract In breast cancer, the prognostic impact of COX2 expression varies widely between studies. We examined the prognostic value of COX2 expression in a large cohort of breast cancer patients treated with primary surgery between 1985 and 1994 and explained the variable results of COX2 expression found in the literature. A tissue microarray was constructed of available tumour material, and ER, PgR, HER2, Ki67 and COX2 were examined by immunohistochemistry. Median follow-up was 19 years. Fifty-five percent (n = 369/677) of patients received no systemic treatment. COX2 was scored using a weighted histoscore. Analysis of COX2 expression in two groups based on the median (148; below vs. above) showed an increased hazard ratio (HR) of 1.35 (95% CI 1.05-1.75, P = 0.021) for disease-free survival (DFS) and of 1.39 (95% CI 1.03-1.82, P = 0.016) for overall survival (OS). However, COX2 did not remain independent in multivariate analysis. In patients with hormone receptor positive tumours, COX2 expression had a negative influence on outcome (low vs. high: DFS: HR 1.37, 95% CI 1.07-1.76, P = 0.013). This effect disappeared when endocrine therapy was administered (low vs. high: DFS: HR 0.93, 95% CI 0.51-1.70, P = 0.811) while it remained statistically significant when endocrine therapy was omitted (low vs. high: DFS: HR 1.48, 95% CI 1.12-1.94, P = 0.005). Our results show that COX2 plays a role in hormonal pathways. Our results can explain the results found in previously published studies.
Introduction
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of death from cancer in women in the western world [1] . Systemic treatment improves disease-free survival (DFS) and overall survival (OS) in patients with early breast cancer [2] . The indication for systemic treatment is based on prognostic and predictive factors [3] . Prognostic factors estimate the patient's risk of relapse in the absence of systemic therapy and include, amongst others, age at diagnosis, tumour grade and lymph node status. Predictive factors estimate the responsiveness of a tumour to a specific treatment, for example, expression of oestrogen receptor (ER) for endocrine therapy and overexpression/amplification of human epidermal growth factor receptor 2 (HER2) for trastuzumab. Prognostic and predictive factors are increasingly important as the relative risk of death from breast cancer is decreased by early diagnosis and improved treatment. Moreover, a substantial proportion of patients with early breast cancer may survive without adjuvant endocrine and/ or chemotherapy. Novel markers are needed to further subcategorize patients for different systemic treatment regimens.
Several epidemiologic and observational studies have examined the relationship between non-steroidal antiinflammatory drugs (NSAIDS) and early breast cancer. In the prospective Women's Health Initiative Observational Study, regular use of NSAIDS was significantly correlated with a reduction in the incidence of breast cancer [4] . Furthermore, the findings of a meta-analysis of 14 studies suggest that use of NSAIDS may be associated with a small decrease in breast cancer risk [5] . The main target of NSAIDS is cyclooxygenase (COX), which exists in two isoforms: COX1 and COX2, which are regulated independently. COX1 is expressed in normal tissue, whereas COX2 is expressed in various human malignancies, like colon and breast cancer. COX2 catalyzes the conversion of arachidonic acid into prostaglandins and increased levels of prostaglandins are associated with carcinogenesis [6] .
A number of studies have examined the impact of COX2 expression in early breast cancer patients [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The results of these studies vary widely, which may be partly explained by the fact that most studies did not stratify patients according to systemic therapy. Moreover, in the majority of these studies, patients received some form of systemic therapy so that reliable data on the prognostic impact of COX2 in the absence of systemic therapy is lacking. This might be important, especially for endocrine therapy, as COX2 catalyzes the conversion of arachidonic acids into prostaglandins which stimulates aromatase and thus formation of estrogens [23] .
We examined the prognostic value of COX2 expression in a cohort of operable breast cancer patients in the Leiden University Medical Centre (LUMC) between 1985 and 1994. About one-third of this group was treated with adjuvant endocrine or chemotherapy. We performed stratified analyses to systemic treatment and assessed the relationship between COX2 expression and established prognostic clinicopathological parameters. We used the guidelines for the reporting of tumour marker studies (REMARK) [24] .
Patients and methods

Patients
The patient population was a consecutive series of all women with non-metastatic breast cancer who received a primary surgical resection (with or without radiotherapy) in the LUMC between 1985 and 1994. Patients with a prior history of cancer (other than basal cell carcinoma or in situ carcinoma) or bilateral tumours were excluded. Age at diagnosis, tumour grade, morphology, TNM stage, local and systemic therapy, locoregional/distant recurrence, second primaries and death were recorded. All tumours were histologically classified and graded by one pathologist (VS). Approval was obtained from the LUMC Medical Ethics Committee.
Preparation of tumour tissue microarrays
Formalin fixed paraffin-embedded tumour blocks of the primary tumour were collected of the pathology department. All blocks were stored at room temperature. Sections were cut for haematoxylin and eosin staining, and histopathologically representative tumour regions were indicated by a pathologist (MvdV) and used for preparation of tumour tissue microarray (TMA) blocks [25] . From each donor block, three 0.6-mm 2 tissue cores were punched from tumour areas and transferred into a recipient paraffin block using a custom-made precision instrument. Fourmicrometre thick sections of the TMAs were cut and processed for immunohistochemistry.
Immunohistochemistry
Tissues were dewaxed in xylene and rehydrated in a graded alcohol series. Antigen retrieval was carried out for 5 min in a pressure cooker in 10 mmol/l sodium-citrate buffer (pH 6.0). Slides were immersed in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity and in a blocking solution (DAKO protein-free serum block) for 60 min to block non-specific binding sites. Immunostaining was performed with COX2 (antihuman) monoclonal antibody (160112; Cayman Chemical Co., Ann Arbor, MI) diluted in antibody diluent (DAKO) at a concentration of 1:100 for 30 min at room temperature. One tumour TMA was stained with and without antibody as a positive and negative control, respectively. Sections were treated with envision (DAKO), and visualization was performed using DAB (DAKO). Finally, tissues were counterstained with haematoxylin and dehydrated through graded alcohols and xylene. Immunostaining for ER, progesterone receptor (PgR), Ki67 and HER2 was carried out using established procedures with the following antibodies: NCL-L-ER-6F11 (Novocastra), monoclonal mouse antihuman progesterone receptor Clone PgR 636 (M3569, DAKO), monoclonal mouse antihuman ki67 antigen Clone MIB-1 (M7240, DAKO) and HercepTest TM for DAKO autostainer (K5207 DAKO), respectively [26] .
Evaluation of immunostaining
It has been shown that TMAs with 2 cores from each tumour is a valuable and accurate method for analysis of protein expression in large archival cohorts and correlates highly with whole-section staining [27, 28] . COX2 immunohistochemical staining was scored independently and in a blind manner using a weighted histoscore. The proportion of cells with cytoplasmic staining was multiplied by the intensity of staining to provide a score of 0-300. Score = (0 9 percentage of cytoplasm not stained) ? (1 9 percentage weakly stained) ? (2 9 percentage moderately stained) ? (3 9 percentage strongly stained) [29] . The first investigator (JvN) scored all cores and the second investigator (CF) scored 33% of cores to ensure consistency, both in a blind manner. The interclass correlation coefficient of cores scored was excellent: 0.928 [30] . The intra-observer variability analysed using Cohen's kappa coefficient was 0.87. All tumours with discordant scores were re-evaluated by both investigators. The mean score of all cores scored by the first investigator was used for analysis.
Oestrogen receptor and progesterone receptor immunohistochemical staining was scored using a weighted histoscore generated by an automated image analysis machine, the Ariol SL-50 Image Analysis System. The suitability of this system has been reported previously [31, 32] . Tumour epithelium was marked for analysis, and the marked areas' quality was assured by a pathologist (DF). The system was trained on the basis of the cellular characteristics of epithelial, stromal and infiltrating non-tumourous cells to produce a trained classifier applicable to all nuclear stains. A positive hormone receptor status was defined as a histoscore of at least 10. Ki67 expression (percentage of positive cells) was also evaluated using the Ariol System. There are different cut points when using Ki67, we used 5. HER2 staining intensity was graded (by DF) in accordance with the HercepTest protocol system as 0, 1?, 2? or 3?. Samples scored as 0, 1? or 2? were considered negative for HER2 overexpression, 3? was considered to be positive.
Study design
The design comprises a retrospective cohort study (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . No stratification or matching was used. The end of follow-up period is 1 January 2009 or death or date of lost of follow-up. Objectives of these retrospective analyses are (independent) correlation of COX2 with survival, relation with systemic therapy and relation with established prognostic clinicopathological parameters. 
Statistical analysis
All data were analysed using the statistical package SPSS for Windows 15.0 (SPSS Inc, Chicago, IL, USA). Descriptive data are given as mean (±standard deviation, SD) or median (range). DFS was calculated from the date of surgery up to the first date of locoregional or distant recurrence, contralateral breast cancer or death by any cause, whichever came first. OS was defined from the date of surgery up to the date of death from any cause. In order to examine if COX2 expression was correlated with DFS and OS, univariate Cox analyses were performed. COX2 expression was normally distributed within the population, for statistical analysis samples were divided into two equal groups (high and low) based on the median histoscore, this cut off was selected to maximise statistical power. Multivariate analyses were performed using the Cox proportional hazards model entering COX2 expression with other significant variables (defined as those with P \ 0.1) on univariate analysis. The relationship between COX2 expression and established prognostic factors was investigated using the v 2 test without Bonferroni correction. All testings were two-tailed with 0.05 as level of significance [33] . Missing data were not used for analyses.
Results
Patients
A total of 667 patients with non-metastatic breast cancer were treated with a primary surgical resection in the LUMC during the study period. TMAs were made from available paraffin tumour blocks from 574/667 (86%) patients. Of these, 369/574 (64%) patients received no systemic treatment, the remaining 205 patients received a mixture of endocrine and/or chemotherapy ( Fig. 1) . The median follow-up for patients alive was 19 years (range 0-23). Clinicopathological and local treatment characteristics are shown in Table 1 .
Distribution of prognostic factors
Oestrogen receptor staining was successful in 94% of tumours (cores were missing, folded or contained no invasive tumour in 6%). Median tumour ER histoscore was 45.77 (range 0-254). PgR staining was successful in 93% of tumours; median tumour PgR histoscore was 25.59 (range 0-300). The interquartile ranges for ER and PgR were 132 and 126, respectively. HER2 expression was successful in 74% of tumours. Overexpression of HER2 was seen in 10% and 90% of tumours had no HER2 overexpression. Ki67 staining was successful in 93%; median tumour Ki67 expression was 2.20 (0-63) and the interquartile range was 6.19.
COX2 expression in tumour tissue
In tumour cells, COX2 staining was observed in the cytoplasm with a granular staining pattern (Fig. 2) . COX2 staining was successful in 88% of tumours (cores were missing, folded or contained no invasive tumour in 12%). COX2 expression was available for 316/369 (86%) cases with no systemic treatment and for 188/205 (92%) cases receiving systemic treatment (Fig. 1) , no significant differences were observed between cases with data available for COX2 expression and those for whom data was not available with respect to conventional prognostic markers (data not shown). Median tumour COX2 histoscore was 148.33 (range 3-278), meaning high COX2 had a histoscore [148 and low COX2 a histoscore B148.
Prognostic value of COX2 expression
In order to analyse the prognostic value of COX2, we analysed data from the patients who were treated with local therapy only ( 
COX2 expression in the hormonal pathway
In order to investigate the influence of COX2 expression on survival in relation to hormone receptor and endocrine therapy, we first investigated COX2 expression in patients with hormone receptor negative tumours (Fig. 4) . In these patients, COX2 expression had no influence on overall survival (log-rank P = 0.593). In univariate analyses of patients with hormone receptor positive tumours, however, low COX2 expression was associated with better survival compared to a high COX2 expression (DFS: HR 1.37 95% CI 1.07-1.76, P = 0.013; OS: HR 1.44, 95% CI 1.11-1.86, P = 0.006). Subsequently, within patients with hormone receptor positive tumours, we analysed the effect of endocrine therapy administration in relation to COX2 expression (Fig. 5 ). COX2 expression levels did not differentiate survival in patients treated with endocrine therapy in univariate analyses (low vs. high; DFS: HR 0.93, 
COX2 expression and clinicopathological parameters
Increased COX2 expression was observed with increasing grade and stage (P \ 0.0001), and tumours from older patients exhibited increased COX2 expression (P \ 0.004; Table 3 ). Both in ER negative and PgR negative tumours exhibited higher COX2 expression levels than hormone receptor positive tumours (Table 3 ). There was no significant correlation between Ki67/HER2 expression and COX2 expression.
Discussion
In breast cancer, a number of studies have explored the relationship between COX2 expression and clinical outcome (Table 4 ) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, to the best of our knowledge, this is the first study to investigate and assess the true impact of COX2 expression on prognosis in breast cancer (i.e. outcome in the absence of systemic therapy). In the current study, elevated levels of COX2 expression were associated with an increased risk of relapse and death in the BCS breast conserving surgery, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, MST mastectomy, PgR progesterone receptor absence of endocrine or chemotherapy in univariate analysis. However, in multivariate analysis, COX2 expression did not provide additional prognostic information over conventional markers like age and lymph node status. Therefore, our data do not support a role for COX2 expression as a prognostic marker independent of conventional clinicopathological criteria. This contradicts much of the published literature (see below). Although the number of patients in the untreated group in the current study is relatively small (369), the hazard ratio for COX2 expression in the multivariate analysis (1.07 for DFS and 1.03 for OS) approaches one. This suggests that even in a significantly larger patient group, COX2 expression would not provide statistically significant additional prognostic information. COX2 plays an evident role in the hormonal pathway. We hypothesised that COX2 expression is associated with a worse outcome in patients with hormone receptor positive tumours compared to patients with hormone receptor negative tumours due to the relationship between COX2 and aromatase expression. In addition, we suggested that administration of endocrine therapy would abolish this prognostic effect of COX2 expression within patients with hormone receptor positive tumours. In patients with hormone negative disease, COX2 had no influence on survival. In addition, both Kaplan-Meier survival analyses and Cox regression analyses showed that COX2 expression had no additional effect in patients with hormone receptor positive tumours who received endocrine therapy. However, in the subgroup of patients in which endocrine therapy was not administrated, COX2 expression was of prognostic significance. These findings suggest that COX2 plays a role in the hormonal pathway in breast cancer. Additionally, these findings suggest that endocrine therapy could be omitted in patients who express of low levels of COX2 with hormone sensitive tumours at a low risk according to current risk stratification. However, to prove this, a randomised controlled trial is needed.
We reviewed 16 previous studies examining the immunohistochemical expression of COX2 expression in breast tumours (Table 4) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Cross comparison between studies and our data was not easy since many studies included very small numbers of tumours, or had short median follow-up (2-9 years) and there was a lack of standardization of COX2 analysis. Most studies used the same antibody (Cayman Chemical Co., Ann Arbor, MI), but different concentrations and incubation times. Also, different methods for evaluation of COX2 expression were used; for example, Spizzo et al. examined COX2 expression using the product of the percentage of stained cells and the intensity, whilst Ristimaki et intensity of stained cells [16, 20] . We used the weighted histoscore because this combines the intensity as well as the percentage of cells stained. Finally, in published studies, COX2 'positivity' was seen in a range of 5-85% of cases. However, arbitrary distinctions between COX2 positive and COX2 negative cases were used. COX2 expression was defined as any positive staining by Schmitz et al., in contrast to Park et al., where at least 80% of cells needed to be stained before the tumour was classified positive [15, 17] . This diversity in methods used for staining, interpretation and analysis of COX2 expression in previous studies complicates comparisons between studies.
In spite of the diversity of methods discussed above, we suggest our results can provide a unifying explanation of the results found in the other studies. Denkert et al. showed a correlation with COX2 expression and DFS in multivariate analysis [9] . However, 63% of tumours in Denkert's study were ER positive (PgR was not shown) and only 23% of patients received endocrine therapy. Therefore, at least 40% of this population was hormone receptor positive and did not receive endocrine therapy. Similar results were seen in the study of Zerkowski et al., where at least 70% of tumours were hormone receptor positive and only 57% of patients received endocrine therapy. The three largest studies included a majority of patients treated prior to 1998 [10, 16, 22] . We regard this as important because results reported by the Early Breast Cancer Trialist' Collaborative Group (following metaanalysis of randomised trials of endocrine therapy in early breast cancer patients) showed a correlation between tumour ER expression and response to endocrine therapy [34] . Prior to this report, endocrine therapy was given on the basis of menopausal status; following the publication of the meta-analysis, endocrine therapy was given based on hormonal status. We believe that the existence of cohorts of ER positive patients who did not received endocrine therapy can explain the results of the earlier studies This may also explain the similarity between our findings and those of Haffty et al. who also showed that COX2 expression was correlated with survival in hormone receptor positive tumours, but not in hormone receptor negative tumours [10] . This hypothesis is readily testable by future studies exploring the impact of COX2 expression in ER positive patients stratified by treatment with endocrine therapy.
In conclusion, in patients who did not receive systemic treatment, increased COX2 expression was not independently prognostic for an increased risk of relapse and death from breast cancer after correction for current clinicopathological markers. COX2 expression was prognostic in patients with hormone receptor positive breast cancer who did not receive endocrine therapy. Studies measuring the impact of COX2 expression in the context of systemic therapies should be reinterpreted in light of this finding and a randomised controlled trial is needed to prove our results. 
